Keywords: |
protein kinase b; cancer survival; controlled study; human cell; promoter region; genetics; liver cell carcinoma; nonhuman; brain tumor; brain neoplasms; endometrium carcinoma; metabolism; hepatocyte nuclear factor 3alpha; gene expression; epidermal growth factor receptor; animal experiment; animal model; immunoglobulin enhancer binding protein; pathology; cell line, tumor; phosphatidylinositol 3 kinase; adrenal cortex carcinoma; ewing sarcoma; gene expression regulation; oncogene; gene expression regulation, neoplastic; lung adenocarcinoma; neoplastic stem cells; epigenetics; epigenesis, genetic; promoter regions, genetic; glioblastoma; histone h3; myc protein; tumor cell line; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; cancer stem cell; vasculotropin a; gene control; androgen receptor; down regulation; thyroid carcinoma; prostate adenocarcinoma; gene regulatory network; cyclin dependent kinase inhibitor 2a; esophagus cancer; stomach adenocarcinoma; hypoxia inducible factor 1alpha; genetic epigenesis; colon adenocarcinoma; oxidative phosphorylation; cyclin dependent kinase 4; notch1 receptor; tumor necrosis factor; rna sequence; clear cell renal cell carcinoma; enhancer region; enhancer elements, genetic; cyclin dependent kinase 6; gene regulatory networks; housekeeping gene; single cell analysis; single-cell analysis; epithelial mesenchymal transition; principal component analysis; mammalian target of rapamycin complex 1; transcription factor sox9; transcription factor runx2; protein c jun; cancer prognosis; spacer dna; guide rna; humans; human; article; rna sequencing; differential gene expression; squamous cell lung carcinoma; clonogenicity; connectome; single-cell rna-seq; single cell rna seq; chromatin immunoprecipitation sequencing; 3d chromatin organization; transitional cell carcinoma of the bladder; structural variants; crispri; hichip; enhancer hubs; enhancer-promoter interactions; oncogenic program; regulatory hubs; pdcd10 gene; wdr49 gene; zbbx gene
|